id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-4282-0014,FDA,FDA-2017-E-4282,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-08-05T04:00:00Z,2019,8,2019-08-05T04:00:00Z,,2019-08-05T19:36:58Z,,0,0,0900006483df7c28
FDA-2017-E-4282-0012,FDA,FDA-2017-E-4282,"Determination of Regulatory Review Period for Purposes of Patent
Extension; TRULANCE",Notice,Determinations,2018-12-04T05:00:00Z,2018,12,2018-12-04T05:00:00Z,2019-02-05T04:59:59Z,2019-01-30T02:05:27Z,2018-26289,0,0,09000064839390a7
FDA-2017-E-4282-0011,FDA,FDA-2017-E-4282,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-11-20T05:00:00Z,2018,11,2018-11-20T05:00:00Z,,2018-11-20T13:06:21Z,,0,0,09000064838eb872
FDA-2017-E-4282-0010,FDA,FDA-2017-E-4282,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T13:04:03Z,,0,0,090000648378acad
FDA-2017-E-4282-0005,FDA,FDA-2017-E-4282,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-09-21T04:00:00Z,2017,9,2017-09-21T04:00:00Z,,2017-09-21T18:48:54Z,,0,0,0900006482b6ba26
FDA-2017-E-4282-0003,FDA,FDA-2017-E-4282,"Providing Regulatory Submissions in Electronic Format--Content of 
the Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2017-09-05T04:00:00Z,2017,9,2017-09-05T04:00:00Z,2018-03-06T04:59:59Z,2018-03-06T14:01:21Z,2017-18506,0,0,0900006482b0c1cb
FDA-2017-E-4282-0004,FDA,FDA-2017-E-4282,Draft Guidance for Industry Providing Regulatory Submissions in Electronic Format--Content of Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling,Other,Guidance,2017-09-05T04:00:00Z,2017,9,2017-09-05T04:00:00Z,,2024-11-07T01:11:09Z,,1,0,0900006482b0c6e5
FDA-2017-E-4282-0001,FDA,FDA-2017-E-4282,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2017-07-18T04:00:00Z,2017,7,2017-07-18T04:00:00Z,,2017-07-18T12:05:36Z,,0,0,090000648293b0e3
FDA-2017-E-4282-0002,FDA,FDA-2017-E-4282,"Patent Extension Application from Cooley LLP (on behalf of Synergy Pharmaceuticals, Inc.)",Other,Application,2017-07-18T04:00:00Z,2017,7,2017-07-18T04:00:00Z,,2017-07-18T12:11:57Z,,0,0,090000648293b0df